Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 11, 2004, Pages 1710-1716

  Subbarayan, Vemparala ^a   Sabichi, Anita L ^a   Kim, Jeri ^a   Llansa, Norma ^a   Logothetis, Christopher J ^a   Lippman, Scott M ^a   Menter, David G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; HYDROXYICOSATETRAENOIC ACID; ISOPROTEIN; LIPOXYGENASE; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; TRANSCRIPTION INITIATION;

ANIMALS; BLOTTING, WESTERN; CATTLE; CELL DEATH; CELLS, CULTURED; HUMANS; LUCIFERASES, FIREFLY; LUMINESCENT AGENTS; MALE; PHOSPHORYLATION; PPAR GAMMA; PROSTAGLANDIN D2; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TRANS-ACTIVATION (GENETICS);

EID: 8344228531     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vamecq J, Latruffe N. Medical significance of peroxisome receptors. Lancet 1999;354:141-8.
2. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
3. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR γ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34.
4. Tokugawa Y, Kunishige I, Kubota Y, et al. Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. Biol Reprod 1998;58:600-7.
5. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999;155:235-45.
6. Tang S, Bhatia B, Maldonado CJ, et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 2002;277:16189-201.
7. Segawa Y, Yoshimura R, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002;51:108-16.
8. Nwankwo JO, Robbins ME. Peroxisome proliferator-activated receptor-γ expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 2001;64:241-5.
9. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A 2000;97:10990-5.
10. Kubota T, Koshizuka K, Williamson E, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
11. Mueller E, Drori S, Aiyer A, et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms. J Biol Chem 2002;277:41925-30.
12. Butler R, Mitchell SH, Tindall DJ, Young CYF. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor-γ ligand, 15-deoxy-Δ-12,14- prostaglandin J2. Cell Growth Differ 2000;11:49-61.
13. Shappell SB, Gupta RA, Manning S, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001;61:497-503.
14. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res 2001;61:2720-6.
15. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991;19:3998.
16. Salas TR, Reddy SA, Clifford JL, et al. Alleviating the suppression of glycogen synthase kinase-3β by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 2003;278:41338-46.
17. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9: 1171-82.
18. Hsi L, Wilson L, Eling T. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor γ. J Biol Chem 2002;277:40549-56.
19. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996;274:2100-3.
20. Zuker M, Jacobson AB. Using reliability information to annotate RNA secondary structures. RNA 1998;4:669-79.
21. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135:798-800.
22. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR γ. Mol Cell 1998;1:465-70.
23. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
24. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998;115:1049-55.
25. Heinlein CA, Ting H-J, Yeh S, Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ. J Biol Chem 1999;274:16147-52.
26. Bhatia B, Maldonado CJ, Tang S, et al. Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 2003;278:25091-100.
27. Tang DG, La E, Kern J, Kehrer JP. Fatty acid oxidation and signaling in apoptosis. Biol Chem 2002;383:425-42.
28. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997;272:18779-89.
29. Short JD, Pfarr CM. Translational regulation of the JunD messenger RNA. J Biol Chem 2002;277:32697-705.
30. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130:479-82S.